A Public-Health-Based Vision for the Management and Regulation of Psychedelics

References

• Abraham, H. D., A. M. Aldridge, and P. Gogia. 1996. The psychopharmacology of hallucinogens. Neuropsychopharmacology 14 (4):285–98. doi:10.1016/0893-133X(95)00136-2.
   PubMed Web of Science ®Google Scholar
• Abramson, H. A., ed. 1967. The use of LSD in psychotherapy and alcoholism. Indianapolis, IN: Bobbs-Merrill.
   Google Scholar
• Albaugh, B. J., and P. O. Anderson. 1974. Peyote in the treatment of alcoholism among American Indians. American Journal of Psychiatry 131 (11):1247–50.
   PubMed Web of Science ®Google Scholar
• Barrett, D., R. Lines, R. Schleifer, R. Elliott, and D. Bewley-Taylor. 2008. Recalibrating the regime: The need for a human rights-based approach to international drug policy. The Beckley Foundation Drug Policy Programme. IHRA, Human Rights Watch, Canadian HIV/AIDS Legal Network, London, UK.
   Google Scholar
• Bogenschutz, M. P., A. A. Forcehimes, J. A. Pommy, C. E. Wilcox, P. Barbosa, and R. J. Strassman. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29 (3):289–99. doi:10.1177/0269881114565144.
   PubMed Web of Science ®Google Scholar
• Boire, R. G. 2000. On cognitive liberty (part one). Journal of Cognitive Liberties 1 (1):7–13.
   Google Scholar
• Brown, T. K. 2013. Ibogaine in the treatment of substance dependence. Current Drug Abuse Review 6 (1):3–16. doi:10.2174/15672050113109990001.
   PubMedGoogle Scholar
• Buxton, J. A., M. Haden, and R. G. Mathias. 2008. The control and regulation of currently illegal drugs. In International Encyclopedia of Public Health, ed. by K. Heggenhougen, and S. Quah. San Diego, CA: Academic Press.
   Google Scholar
• Calabrese, J. D. 2013. A different medicine: Postcolonial healing in the Native American Church. Oxford,UK: Oxford University Press.
   Google Scholar
• Canadian Drug Policy Coalition. 2012. Changing the frame: A new approach to drug policy in Canada. Vancouver, BC: Simon Fraser University.
   Google Scholar
• Canadian Public Health Association. 2014. A new approach to managing illegal psychoactive substances in Canada. Ottawa, ON: Canadian Public Health Association.
   Google Scholar
• Carhart-Harris, R. L., M. Kaelen, M. Bolstridge, T. M. Williams, L. T. Williams, R. Underwood, A. Feilding, and D. J. Nutt. 2016. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychological Medicine 1–12. doi:10.1017/S0033291715002901.
   Web of Science ®Google Scholar
• Carvalho, M. C., M. P. de Sousa, P. Frango, P. Dias, J. Carvalho, M. Rodrigues, and T. Rodrigues. 2014. Crisis intervention related to the use of psychoactive substances in recreational settings: Evaluating the Kosmicare Project at Boom Festival. Current Drug Abuse Review 7 (2):81–100. doi:10.2174/1874473708666150107115515.
   PubMedGoogle Scholar
• Chambliss, W. J. 1994. Another lost war: The costs and consequences of drug prohibition. Social Justice 22 (2):101–23.
   Google Scholar
• Coomber, R., and N. South, eds. 2004. Drug use and cultural contexts “beyond the West”: Tradition, change and post-colonialism. London, UK: Free Association Books.
   Google Scholar
• Cottrell, R. C. 2015. Sex, drugs, and rock ‘n roll: The rise of America’s 1960s counterculture. Lanham, MD: Rowman & Littlefield.
   Google Scholar
• Day, D. C. 2007. The capable minor’s healthcare: Who decides? The Canadian Bar Review 86 (3):379–420.
   Google Scholar
• Dobkin de Rios, M. 1990. Hallucinogens: Cross cultural perspectives. Long Grove, IL: Waveland Press Inc.
   Google Scholar
• Doblin, R. 1991. Pahnke’s “Good Friday experiment”: A long-term follow-up and methodological critique. The Journal of Transpersonal Psychology 23:1.
   Google Scholar
• Durrant, R., and J. Thakker. 2003. Substance use and abuse: Cultural and historical perspectives. London, UK: Sage Publications.
   Google Scholar
• Dyck, E. 2005. Flashback: Psychiatric experiementation with LSD in historical perspective. Canadian Journal of Psychiatry 50 (7):381–88.
   PubMed Web of Science ®Google Scholar
• Dyck, E. 2008. Psychedelic psychiatry: LSD from clinic to campus. Baltimore, MD: Johns Hopkins University Press.
   Google Scholar
• EMCDDA. 2015. European drug report 2015: Trends and developments. Lisbon, Portugal: European Monitoring Centre for Drug and Drug Addiction.
   Google Scholar
• Fernandez, J. W., and R. L. Fernandez. 2001. Returning to the path: The use of ibogaine in an equatorial African Ritual Context and the binding of time, space and social relationships. The Alkaloids: Chemistry and Biology 56:235–247.
   Google Scholar
• Frank, J., E. Di Ruggiero, and B. Moloughney. 2004. Proceedings of the think tank on the future of public health in Canada. Canadian Journal of Public Health 95 (1):6–11.
   PubMed Web of Science ®Google Scholar
• Furst, P. T. 1976. Hallucinogens and culture. San Francisco, CA: Chandler & Sharp.
   Google Scholar
• Gable, R. S. 1993. Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically. The American Journal of Drug and Alcohol Abuse 19 (3):263–81. doi:10.3109/00952999309001618.
   PubMed Web of Science ®Google Scholar
• Gable, R. S. 2006. The toxicity of recreational drugs. American Scientist 94:206–08. doi:10.1511/2006.59.3484.
   Web of Science ®Google Scholar
• Global Commission on Drug Policy. 2014. Taking control: Pathways to drug policies that work. Geneva, Switzerland: Global Commission on Drug Policy.
   Google Scholar
• Griffiths, R., W. Richards, M. Johnson, U. McCann, and R. Jesse. 2008. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology 22 (6):621–32. doi:10.1177/0269881108094300.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., W. A. Richards, U. McCann, and R. Jesse. 2006. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187 (3):268–83. doi:10.1007/s00213-006-0457-5.
   PubMed Web of Science ®Google Scholar
• Grinspoon, L., and J. Bakalar. 1997. Psychedelic drugs reconsidered. New York, NY: The Lindesmith Centre.
   Google Scholar
• Grob, C. S., A. L. Danforth, G. S. Chopra, M. Hagerty, C. R. McKay, A. L. Halberstadt, and G. R. Greer. 2011. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry 68 (1):71–78. doi:10.1001/archgenpsychiatry.2010.116.
   PubMed Web of Science ®Google Scholar
• Grob, C. S., D. J. McKenna, J. C. Callaway, G. S. Brito, E. S. Neves, G. Oberlander, O. L. Saide, E. Labigalini, C. Tacla, C. T. Miranda, R. J. Strassman, and K. B. Boone. 1996. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. The Journal of Nervous and Mental Disease 184 (2):86–94. doi:10.1097/00005053-199602000-00004.
   PubMed Web of Science ®Google Scholar
• Grof, S. 2008. LSD Psychotherapy, 4th edition. Santa Cruz, CA: Multidisciplinary Association for Psychedelic Studies.
   Google Scholar
• Grund, J.-P. C. 1993. Drug use as social ritual: Functionality, symbolism and determinants of self-regulation, Vol. 4. Rotterdam, The Netherlands: IVO.
   Google Scholar
• Haden, M. 2008. Controlling illegal stimulants: A regulated market model. Harm Reduction Journal 5 (1):1. doi:10.1186/1477-7517-5-1.
   PubMed Web of Science ®Google Scholar
• Haden, M., and B. Emerson. 2014. A vision for cannabis regulation: A public health approach based on lessons learned from the regulation of alcohol and tobacco. Open Medicine 8 (2):73–80.
   Google Scholar
• Halpern, J. H., and H. G. Pope. 1999. Do hallucinogens cause residual neuropsychological toxicity? Drug and Alcohol Dependence 53 (3):247–56. doi:10.1016/S0376-8716(98)00129-X.
   PubMed Web of Science ®Google Scholar
• Halpern, J. H., and H. G. Pope. 2003. Hallucinogen persisting perception disorder: What do we know after 50 years? Drug and Alcohol Dependence 53 (3):247–56. doi:10.1016/S0376-8716(98)00129-X.
   Web of Science ®Google Scholar
• Halpern, J. H., A. R. Sherwood, T. Passie, K. C. Blackwell, and A. J. Ruttenber. 2008. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Drug and Alcohol Review 14 (8):SR15–22.
   Google Scholar
• Harman, W., R. H. McKim, R. H. Mogar, R. E. Fadiman, and M. J. Stolaroff. 1966. Psychedelic agents in creative problem-solving: A pilot study. Psychological Reports 19 (1):211–27. doi:10.2466/pr0.1966.19.1.211.
   PubMed Web of Science ®Google Scholar
• Health Canada. 2012. Canadian Alcohol and Drug Use Monitoring Survey. Ottawa, Canada: Health Canada.
   Google Scholar
• Health Officers Council of British Columbia. 2005. A public health approach to drug control in Canada: Discussion paper. Victoria, BC: HOC B.C.
   Google Scholar
• Health Officers Council of British Columbia. 2011. Public health perspectives for regulating psychoactive substances. Victoria, BC: HOC B.C.
   Google Scholar
• Hendricks, P. S., C. B. Clark, M. W. Johnson, K. R. Fontaine, and K. L. Cropsey. 2014. Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. Journal of Psychopharmacology 28 (1):62–66. doi:10.1177/0269881113513851.
   PubMed Web of Science ®Google Scholar
• Hendricks, P. S., C. B. Thorne, C. B. Clark, D. W. Coombs, and M. W. Johnson. 2015. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology 29 (3):280–88. doi:10.1177/0269881114565653.
   PubMed Web of Science ®Google Scholar
• Hill, T. W. 1990. Peyotism and the control of heavy drinking: The Nebraska Winnebago in the early 1900s. Human Organization 49 (3):255–65. doi:10.17730/humo.49.3.m70273175tn234r1.
   Web of Science ®Google Scholar
• Johansen, P. O., and T. S. Krebs. 2015. Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of Psychopharmacology 29 (3):270–79. doi:10.1177/0269881114568039.
   PubMed Web of Science ®Google Scholar
• Johnson, M., W. Richards, and R. Griffiths. 2008. Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology 22 (6):603–20. doi:10.1177/0269881108093587.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, M. P. Cosimano, and R. R. Griffiths. 2014. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology 28 (11):983–92. doi:10.1177/0269881114548296.
   PubMed Web of Science ®Google Scholar
• Johnston, L. D., P. M. O’Malley, R. A. Miech, J. G. Bachman, and J. E. Schulenberg. 2015. Monitoring the future: National survey results on drug use. Ann Arbor, MI: The University of Michigan Institute for Social Research.
   Google Scholar
• King County Bar Association: Drug Policy Project. 2005. Controlling psychoactive substances: The current system and alternative models. Seattle, WA: King County Bar Association.
   Google Scholar
• Knipe, E. 1995. Culture, society, and drugs: The social science approach to drug use. Prospect Heights, IL: Waveland Press.
   Google Scholar
• Krebs, T. S., and P. O. Johansen. 2012. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. Journal of Psychopharmacology 26 (7):994–1002. doi:10.1177/0269881112439253.
   PubMed Web of Science ®Google Scholar
• Krebs, T. S., and P. O. Johansen. 2013. Psychedelics and mental health: A population study. PLoS One 8:8. doi:10.1371/journal.pone.0063972.
   Web of Science ®Google Scholar
• Kurland, A. A., S. Grof, W. N. Pahnke, and L. E. Goodman. 1973. Psychedelic drug assisted psychotherapy in patients with terminal cancer. In Psychopharmacological agents for the terminally ill and bereaved, ed. by I. K. Malitz, S. Goldberg, and A. H. Kurtsher, 86–133. New York, NY: Columbia University Press.
   Google Scholar
• Labate, B. C. and C. Cavnar, eds. 2016. Peyote: History, tradition, politics, and conservation. Santa Barbara, CA: Praeger.
   Google Scholar
• Labate, B. C., and K. Feeney. 2012. Ayahuasca and the process of regulation in Brazil and internationally: Implications and challenges. International Journal of Drug Policy 23 (2):154–61. doi:10.1016/j.drugpo.201106.006.
   PubMed Web of Science ®Google Scholar
• Langlitz, N. 2013. Neuropsychedelia: The revival of hallucinogen research since the decade of the Brain. Berkley, CA: University of California Press.
   Google Scholar
• Last, J. M. 2006. In A dictionary of public health. Oxford, UK: Oxford University Press.
   Google Scholar
• Leary, T. 1965. Turn on, tune in, drop out. Oakland, CA: Ronin Publishing Inc.
   Google Scholar
• MacLean, K. A., M. W. Johnson, and R. R. Griffiths. 2011. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology 25 (11):1453–61. doi:10.1177/0269881111420188.
   PubMed Web of Science ®Google Scholar
• MacRae, E. 2004. The ritual use of ayahuasca by three Brazilian religions. In Drug use and cultural contexts “beyond the West”: Tradition, change and post-colonialism, ed. by R. Coomber, and N. South, 27–45. London, UK: Free Association Books.
   Google Scholar
• Mitchell, C. N. 1986. A justice-based argument for the uniform regulation of psychoactive drugs. McGill Law Journal 31(2):212–63.
   Google Scholar
• Mithoefer, M. C. 2013. A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder. Santa Cruz, CA: Multidisciplinary Association for Psychedelic Studies (MAPS).
   Google Scholar
• Mithoefer, M. C., M. T. Wagner, A. T. Mithoefer, L. Jerome, and R. Doblin. 2010. The safety and efficacy of {±}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology 25 (4):439–52. doi:10.1177/0269881110378371.
   PubMed Web of Science ®Google Scholar
• Mithoefer, M. C., M. T. Wagner, A. T. Mithoefer, L. Jerome, S. F. Martin, B. Yazar-Klosinski, Y. Michel, T. D. Brewerton, and R. Doblin. 2013. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. Journal of Psychopharmacology 27 (1):28–39. doi:10.1177/0269881112456611.
   PubMed Web of Science ®Google Scholar
• Mojeiko, V. 2007. Psychedelic emergency services: Report from burning man 2007. MAPS Bulletin 17 (3):15–17.
   Google Scholar
• Moreno, F. A., C. B. Wiegand, E. K. Taitano, and P. L. Delgado. 2006. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. The Journal of Clinical Psychiatry 67 (11):1735–40. doi:10.4088/JCP.v67n1110.
   PubMed Web of Science ®Google Scholar
• Myerhoff, B. G. 1974. Peyote hunt: The sacred journey of the Huichol Indians. Ithaca, NY: Cornell University Press.
   Google Scholar
• Nicol, J. J., M. C. Yarema, G. R. Jones, W. Martz, R. A. Purssell, J. C. MacDonald, I. Wishart, M. Durigon, D. Tzemis, and J. A. Buxton. 2015. Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: A case series. Canadian Medical Association Journal: Open 3 (1):E83–90. doi:10.9778/cmajo.20140070.
   Google Scholar
• Nutt, D. J., L. A. King, and D. E. Nichols. 2013. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews Neuroscience 14 (8):577–85. doi:10.1038/nrn3530.
   PubMed Web of Science ®Google Scholar
• Nutt, D. J., L. A. King, and L. D. Phillips. 2010. Drug harms in the UK: A multicriteria decision analysis. The Lancet 376 (9752):1558–65. doi:10.1016/S0140-6736(10)61462-6.
   PubMed Web of Science ®Google Scholar
• Pahnke, W. 1966. Implications of LSD and experimental mysticism. Journal of Religion and Health 5 (3):175–208. doi:10.1007/BF01532646.
   PubMedGoogle Scholar
• Pahnke, W. 1970. The psychedelic mystical experience in the human encounter with death. Psychedelic Review 11:3–20.
   Google Scholar
• Rhodes, T., and D. Hedrich. 2010. Harm reduction: Evidence, impacts and challenges. City of Luxembourg, Luxembourg: European Monitoring Centre for Drugs and Drug Addiction.
   Google Scholar
• Richards, W. 2015. Sacred knowledge: Psychedelics and religious experiences. New York, NY: Columbia University Press.
   Google Scholar
• Ritter, A. 2009. How do drug policy makers access research evidence? International Journal of Drug Policy 20:70–75. doi:10.1016/j.drugpo.2007.11.017.
   PubMed Web of Science ®Google Scholar
• Roberts, A. R., and G. S. Everly. 2006. A meta-analysis of 36 crisis intervention studies. Brief Treatment and Crisis Intervention 6:10–21. doi:10.1093/brief-treatment/mhj006.
   Google Scholar
• Rolles, S. 2009. After the war on drugs: Blueprint for regulation. Bristol, UK: Transform Drug Policy Foundation.
   Google Scholar
• Rucker, J. J. 2015. Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. British Medical Journal 350:h2902. doi:10.1136/bmj.h2902.
   PubMed Web of Science ®Google Scholar
• Sanches, R. F., F. D. L. Osório, R. G. Dos Santos, L. R. H. Macedo, J. P. Maia-de-Oliveira, L. Wichert-Ana, D. B. de Araujo, J. Riba, J. A. S. Crippa, and J. E. C. Hallak. 2016. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression. Journal of Clinical Psychopharmacology 36 (1):77–81. doi:10.1097/JCP.0000000000000436.
   PubMed Web of Science ®Google Scholar
• Savage, C., and L. McCabe. 1973. Residential psychedelic (LSD) therapy for the narcotic addict. Archives of General Psychiatry 28 (6):808–14. doi:10.1001/archpsyc.1973.01750360040005.
   PubMed Web of Science ®Google Scholar
• Schenberg, E. E., M. A. de Castro Comis, B. R. Chaves, and D. X. Da Silveira. 2014. Treating drug dependence with the aid of ibogaine: A retrospective study. Journal of Psychopharmacology 28 (11):993–1000. doi:10.1177/0269881114552713.
   PubMed Web of Science ®Google Scholar
• Sessa, B. 2005. Can psychedelics have a role in psychiatry once again? The British Journal of Psychiatry 186:457–58. doi:10.1192/bjp.186.6.457.
   PubMed Web of Science ®Google Scholar
• Sessa, B. 2012. The psychedelic renaissance: Reassessing the role of psychedelic drugs in the 21st century psychiatry and society. London, UK: Muswell Hill Press.
   Google Scholar
• Sewell, R. A., J. H. Halpern, and H. G. Pope Jr. 2006. Response of cluster headache to psilocybin and LSD. Neurology 66 (12):1920–22. doi:10.1212/01.wnl.0000219761.05466.43.
   PubMed Web of Science ®Google Scholar
• Stewart, O. C. 1987. Peyote Religion. Norman, OK: University of Oklahoma Press.
   Google Scholar
• Stolaroff, M. J. 1997. The secret chief: Conversations with a pioneer of the underground psychedelic therapy movement. Charlotte, NC: Multidisciplinary Association for Psychedelic Studies (MAPS).
   Google Scholar
• Thomas, G., P. Lucas, N. R. Capler, K. W. Tupper, and G. Martin. 2013. Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Current Drug Abuse Review 6 (1):30–42. doi:10.2174/15733998113099990003.
   PubMedGoogle Scholar
• Tupper, K. W. 2003. Entheogens and education: Exploring the potential of psychoactives as educational tools. Journal of Drug Education and Awareness 1 (2):145–161.
   Google Scholar
• Tupper, K. W. 2014. Sex, drugs and the honour roll: The perennial challenges of addressing moral purity issues in schools. Critical Public Health 24 (2):115–31. doi:10.1080/09581596.2013.862517.
   Web of Science ®Google Scholar
• Tupper, K. W., E. Wood, R. Yensen, and M. W. Johnson. 2015. Psychedelic medicine: A re-emerging therapeutic paradigm. Canadian Medical Association Journal 187 (14):1054–59. doi:10.1503/cmaj.141124.
   PubMed Web of Science ®Google Scholar
• U.N.O.D.C. 2015. International standards on drug use prevention. Vienna, Austria: United Nations.
   Google Scholar
• Van Ree, E. 1999. Drugs as a human right. International Journal of Drug Policy 10 (2):89–98. doi:10.1016/S0955-3959(99)00008-0.
   Google Scholar
• Walsh, C. 2016. Psychedelics and cognitive liberty: Reimagining drug policy through the prism of human rights. International Journal of Drug Policy 29:80–87. doi:10.1016/j.drugpo.2015.12.025.
   PubMed Web of Science ®Google Scholar
• Walsh, Z., P. Hendricks, S. Smith, D. S. Kosson, M. S. Thiessen, P. Lucas, and M. T. Swogger. 2016. Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use. Journal of Psychopharmacology 1 (7). doi:10.1177/0269881116642538.
   Web of Science ®Google Scholar
• Werb, D., E. J. Mills, K. Debeck, T. Kerr, J. S. Montaner, and E. Wood. 2011. The effectiveness of anti-illicit-drug public-service announcements: A systematic review and meta-analysis. Journal of Epidemiology & Community Health 65 (10):834–40. doi:10.1136/jech.2010.125195.
   PubMed Web of Science ®Google Scholar
• Winkelman, M., and T. Roberts. 2007. Psychedelic medicine: New evidence for hallucinogenic substances as treatments. Westport, CT: Praeger Publishers.
   Google Scholar
• Winkelman, M. J. and T. B. Roberts, eds. 2007. Psychedelic medicine: New evidence for hallucinogenic substances as treatments. Westport, CT: Praeger.
   Google Scholar
• Wodak, A. 2007. Ethics and drug policy. Psychiatry 6 (2):59–62. doi:10.1016/j.mppsy.2007.01.001.
   Google Scholar
• World Health Organization. 1986. Ottawa charter for health promotion. Geneva, Switzerland: World Health Organization.
   Google Scholar
• Zinberg, N. E. 1984. Drug, set and setting: The basis for controlled intoxicant use. New Haven, CT: Yale University Press.
   Google Scholar